- ICH GCP
- USA klinikai vizsgálatok nyilvántartása
- Klinikai vizsgálat NCT07633665
PMCF Study on the Effectiveness and Safety of BIODENTOSS® and DWC® Dental Implants and Superstructures
Post-Market Clinical Follow-Up (PMCF) Study on the Effectiveness and Safety of BIODENTOSS® and DWC® Dental Implants and Superstructures
A tanulmány áttekintése
Állapot
Körülmények
Részletes leírás
Tanulmány típusa
Beiratkozás (Becsült)
Fázis
- Nem alkalmazható
Kapcsolatok és helyek
Tanulmányi kapcsolat
- Név: Abdullah Sari, Met. Eng.
- Telefonszám: +90 (332) 516 16 91
- E-mail: kaliteyonetimi@dome.com.tr
Tanulmányi helyek
-
-
-
Konya, Törökország (Türkiye), 42130
- Toborzás
- Selcuk University, Faculty of Dentistry, Dept. of Oral and Maxillofacial Surgery.
-
Kapcsolatba lépni:
- Abdullah Kalayci, Professor
- Telefonszám: +90 (536) 543 25 87
- E-mail: abdullahkalayci@hotmail.com
-
Alkutató:
- Serhan Akman, Professor
-
Alkutató:
- Tuba Yilmaz Savas, Asst. Prof.
-
-
Részvételi kritériumok
Jogosultsági kritériumok
Tanulmányozható életkorok
- Felnőtt
- Idősebb felnőtt
Egészséges önkénteseket fogad
Leírás
Inclusion Criteria:
- 18 years of age or older,
- Male or female,
- Subjects with missing tooth who require dental implant treatment,
- At least 2 months elapsed since tooth extraction,
- General health status suitable for implantation,
- Not legally restricted (e.g., soldier, convict),
- Provision of signed Informed Consent Form (ICF)
Exclusion Criteria:
- Suspected or confirmed pregnancy or breastfeeding,
- Disorders preventing adequate daily oral hygiene,
- Hypersensitivity/allergy to titanium or implant components,
- Inappropriate interarch relationship or parafunction (e.g., bruxism),
- Bone/soft tissue deficiency requiring augmentation,
- Active periodontal infection or untreated oral pathologies,
- Unstable systemic diseases affecting wound healing (e.g., diabetes),
- Use of immunosuppressive drug therapy due to systemic disorders, organ transplantation, or any other medical conditions,
- Hematological disorders or current use of anticoagulants (such as Warfarin, dabigatran or related therapies),
- Presence of osteoporosis and/or any disease condition affecting bone metabolism,
- Presence of an active systemic infection, or any health condition or ongoing treatment (e.g., radiotherapy, bisphosphonate therapy) that contraindicates elective surgery,
- Recent myocardial infarction or cerebrovascular event,
- Individuals who consume high doses of alcohol, cigarettes, or tobacco products and are unable to control their usage,
- Participation in another interventional clinical study.
Tanulási terv
Hogyan készül a tanulmány?
Tervezési részletek
- Elsődleges cél: Egyéb
- Kiosztás: Nem véletlenszerű
- Beavatkozó modell: Párhuzamos hozzárendelés
- Maszkolás: Nincs (Open Label)
Fegyverek és beavatkozások
Résztvevő csoport / kar |
Beavatkozás / kezelés |
|---|---|
|
Kísérleti: BIODENTOSS Cohort
This cohort includes participants receiving BIODENTOSS bone-level dental implants (conical or cylindrical models) and compatible superstructures for the restoration of missing teeth.
Patients will undergo standard surgical implantation followed by prosthetic restoration at 3 to 4 months post-implantation.
Safety and efficacy outcomes-including implant survival/success rates, stability, marginal bone loss, chewing function, and oral health-related quality of life-will be monitored prospectively across a 24-month follow-up period.
Data collected for this cohort will be analyzed and reported independently via descriptive and longitudinal statistics, with no statistical comparison intended against other cohorts.
|
Surgical placement of CE-marked BIODENTOSS bone-level dental implants, available in conical or cylindrical models, with diameters ranging from 3.4 mm to 6.0 mm and lengths from 7.5 mm to 13 mm.
Implants feature an SLA (Sandblasted, Large-grit, Acid-etched) surface texture and a 22-degree conical internal hex connection.
Following an osseointegration period, prosthetic restoration will be completed using compatible superstructures, including cover screws, healing abutments, and various types of prosthetic abutments based on clinical indications.
|
|
Kísérleti: DWC Cohort
This cohort includes participants receiving DWC bone-level dental implants (cylindrical or active threaded) and compatible superstructures for the restoration of missing teeth.
Patients will undergo standard surgical implantation followed by prosthetic restoration at 3 to 4 months post-implantation.
Safety and efficacy outcomes-including implant survival/success rates, stability, marginal bone loss, chewing function, and oral health-related quality of life-will be monitored prospectively across a 24-month follow-up period.
Data collected for this cohort will be analyzed and reported independently via descriptive and longitudinal statistics, with no statistical comparison intended against other cohorts.
|
Surgical placement of CE-marked DWC bone-level dental implants, available in cylindrical or active threaded models, with diameters ranging from 3.3 mm to 4.8 mm and lengths from 8 mm to 15 mm.
Implants feature an SLA (Sandblasted, Large-grit, Acid-etched) surface texture and a 22-degree conical internal hex connection.
Following an osseointegration period, prosthetic restoration will be completed using compatible superstructures, including cover screws, healing abutments, and various types of prosthetic abutments based on clinical indications.
|
Mit mér a tanulmány?
Elsődleges eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Implant Success and Satisfactory Survival Rate
Időkeret: 6, 12, 18, and 24 months post-implantation.
|
The percentage of functional implants in each cohort meeting the 2007 International Congress of Oral Implantologists (ICOI) Pisa Consensus Conference Health Scale criteria. Multiple clinical/radiographic parameters (pain, mobility, bone loss, exudate) are aggregated to classify each implant into a single category: Group I (Success: no pain/mobility, <2mm bone loss, no exudate); Group II (Satisfactory Survival: no pain/mobility, 2-4mm bone loss, no exudate); Group III (Compromised Survival: potential sensitivity, no mobility, >4mm bone loss [<50% of implant body], pocket depth >7mm, potential exudate); or Group IV (Failure: pain, mobility, bone loss >1/2 implant length, or uncontrolled exudate). To arrive at the single reported value, data are aggregated by calculating the combined percentage of implants classified into Group I and Group II out of the total implants evaluated in each cohort. |
6, 12, 18, and 24 months post-implantation.
|
|
Implant Stability Measured by Resonance Frequency Analysis
Időkeret: Immediate post-implantation (baseline) and pre-loading (at 3 months for mandibular implants or 4 months for maxillary implants)
|
Quantitative assessment of implant stability within each independent cohort using non-invasive Resonance Frequency Analysis (RFA).
Individual implant stability will be reported based on the Implant Stability Quotient (ISQ) scale, ranging from 1 to 100.
Higher values indicate greater stability, with an ISQ score ≥ 70 reflecting high stability.
|
Immediate post-implantation (baseline) and pre-loading (at 3 months for mandibular implants or 4 months for maxillary implants)
|
|
Percentage of Implants With Zero Clinical Mobility
Időkeret: At 6, 12, 18, and 24 months post-implantation (all post-loading follow-up visits).
|
Assessment of post-loading implant stability evaluated via manual clinical examination.
Clinical stability is measured by vertical and horizontal forces and graded using Mühlemann's Mobility Index, which ranges from 0 to 4 (where 0 indicates normal/physiological movement and 4 indicates vertical mobility).
The single reported value will be the percentage of implants within each independent cohort achieving a mobility index score of "0" (lack of clinical mobility), indicating successful osseointegration.
|
At 6, 12, 18, and 24 months post-implantation (all post-loading follow-up visits).
|
|
Incidence of Complications and Adverse Events
Időkeret: Throughout the 24-month follow-up period.
|
Safety data will be collected by recording all adverse events (AEs) and complications encountered during the 24-month follow-up period.
This includes intraoperative complications (e.g., bone fenestration/dehiscence, nerve injury), device-related failures (e.g., implant fracture, loss of stability), and any postoperative adverse events (e.g., infection, peri-implant mucositis, or prosthetic component loosening).
|
Throughout the 24-month follow-up period.
|
Másodlagos eredményintézkedések
Eredménymérő |
Intézkedés leírása |
Időkeret |
|---|---|---|
|
Marginal Bone Loss (MBL)
Időkeret: 6, 12, 18, and 24 months post-implantation.
|
Radiographic assessment of bone level changes (mesial/distal) using digital panoramic/periapical radiographs.
|
6, 12, 18, and 24 months post-implantation.
|
|
Chewing Function and Chewing Satisfaction
Időkeret: Baseline and 6, 12, 18, 24 months.
|
Assessed independently within each cohort.
Chewing function will be verified via clinical occlusion control using articulation paper.
Patient chewing satisfaction will be scored directly by the participant using a 5-point Likert scale (ranging from 1: not satisfied at all, to 5: very satisfied).
|
Baseline and 6, 12, 18, 24 months.
|
|
Oral Health-Related Quality of Life (OHRQoL)
Időkeret: Baseline and 6, 12, 24 months.
|
Assessed independently within each cohort using the Oral Health Impact Profile-14 (OHIP-14) questionnaire.
The scale consists of 14 items scored on a Likert scale, with total scores ranging from 0 to 56.
Lower overall scores indicate superior OHRQoL and better clinical outcomes.
|
Baseline and 6, 12, 24 months.
|
Együttműködők és nyomozók
Nyomozók
- Kutatásvezető: Abdullah Kalayci, Professor, Selcuk University Faculty of Dentistry
Tanulmányi rekorddátumok
Tanulmány főbb dátumok
Tanulmány kezdete (Tényleges)
Elsődleges befejezés (Becsült)
A tanulmány befejezése (Becsült)
Tanulmányi regisztráció dátumai
Először benyújtva
Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak
Első közzététel (Tényleges)
Tanulmányi rekordok frissítései
Utolsó frissítés közzétéve (Tényleges)
Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak
Utolsó ellenőrzés
Több információ
A tanulmányhoz kapcsolódó kifejezések
Kulcsszavak
További vonatkozó MeSH feltételek
Egyéb vizsgálati azonosító számok
- INFO_CLC_2301
- 2024-170 (Egyéb azonosító: Turkish Medicines and Medical Devices Agency (TITCK))
Terv az egyéni résztvevői adatokhoz (IPD)
Tervezi megosztani az egyéni résztvevői adatokat (IPD)?
IPD terv leírása
Gyógyszer- és eszközinformációk, tanulmányi dokumentumok
Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz
Egy amerikai FDA által szabályozott eszközterméket tanulmányoz
Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .